Covalent modification of target lysines by SUMO (small ubiquitin-like modifier) modulates processes such as protein localization, transcription, nuclear transport, mitosis, DNA replication and repair, signal transduction, and viral reproduction. SUMO does not seem to be involved in protein degradation and may in fact function as an antagonist of ubiquitin in the degradation process. The SUMO family consists of SUMO1 and closely related homologs SUMO2, SUMO3, and SUMO4. Sumoylation has been shown to regulate a wide range of proteins, including MDM2, PIAS, PML, RanGAP1, RanBP2, p53, p73, HIPK2, TEL, c-Jun, Fas, Daxx, TNFRI, Topo-I, Topo-II, PARK2, WRN, Sp100, IkB-alpha, Androgen receptor (AR), GLUT1/4, CaMK, DNMT3B, TDG, HIF1A, CHD3, EXOSC9, RAD51, and viral targets such as CMV-IE1/2, EBV-BZLF1, and HPV/BPV-E1.
Target |
SUMO1 |
Reactivity |
Human |
Host |
Rabbit |
Clonality |
Polyclonal |
Tested Applications |
WB, IHC, IF/ICC, FCM |
Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
Immunogen |
KLH-conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human SUMO1. |
Purification |
Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
Isotype |
IgG |
Conjugation |
Unconjugated |
Storage |
Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles. |
Swiss Prot |
P63165
|
NCBI Accession |
NP_001005781.1
NP_001005782.1
NP_003343.1
|
Buffer |
PBS containing 0.09% sodium azide. |
UNSPSC Code |
12352203 |
Availability |
Shipped within 5-10 working days. |
Note |
This product is for research use only. |